These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 26560643)

  • 21. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study.
    Jenkins CR; Celli B; Anderson JA; Ferguson GT; Jones PW; Vestbo J; Yates JC; Calverley PM
    Eur Respir J; 2012 Jan; 39(1):38-45. PubMed ID: 21737561
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A post hoc pooled analysis of exacerbations among US participants in randomized controlled trials of tiotropium.
    Anzueto A; Niewoehner DE; Leimer I; Rühmkorf F; Celli BR; Decramer M; Tashkin DP
    Respir Med; 2013 Dec; 107(12):1912-22. PubMed ID: 23969305
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exacerbations of chronic obstructive pulmonary disease.
    Wedzicha JA; Donaldson GC
    Respir Care; 2003 Dec; 48(12):1204-13; discussion 1213-5. PubMed ID: 14651761
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association between incidence of acute exacerbation and medication therapy in patients with COPD.
    Suh DC; Lau H; La HO; Choi IS; Geba GP
    Curr Med Res Opin; 2010 Feb; 26(2):297-306. PubMed ID: 19961283
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence.
    Blais L; Forget A; Ramachandran S
    Clin Ther; 2010 Jul; 32(7):1320-8. PubMed ID: 20678680
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhaled corticosteroids in chronic obstructive pulmonary disease and risk of death and hospitalization: time-dependent analysis.
    Fan VS; Bryson CL; Curtis JR; Fihn SD; Bridevaux PO; McDonell MB; Au DH
    Am J Respir Crit Care Med; 2003 Dec; 168(12):1488-94. PubMed ID: 14525798
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of salmeterol/fluticasone via single versus separate inhalers on exacerbations in severe/very severe COPD.
    Hagedorn C; Kässner F; Banik N; Ntampakas P; Fielder K
    Respir Med; 2013 Apr; 107(4):542-9. PubMed ID: 23337300
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High body mass index and risk of exacerbations and pneumonias in individuals with chronic obstructive pulmonary disease: observational and genetic risk estimates from the Copenhagen General Population Study.
    Çolak Y; Afzal S; Lange P; Nordestgaard BG
    Int J Epidemiol; 2016 Oct; 45(5):1551-1559. PubMed ID: 27118560
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Physical activity in COPD patients decreases short-acting bronchodilator use and the number of exacerbations.
    Katajisto M; Koskela J; Lindqvist A; Kilpeläinen M; Laitinen T
    Respir Med; 2015 Oct; 109(10):1320-5. PubMed ID: 26298024
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tiotropium versus salmeterol for the prevention of exacerbations of COPD.
    Vogelmeier C; Hederer B; Glaab T; Schmidt H; Rutten-van Mölken MP; Beeh KM; Rabe KF; Fabbri LM;
    N Engl J Med; 2011 Mar; 364(12):1093-1103. PubMed ID: 21428765
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacologic treatments for chronic obstructive pulmonary disease: a mixed-treatment comparison meta-analysis.
    Baker WL; Baker EL; Coleman CI
    Pharmacotherapy; 2009 Aug; 29(8):891-905. PubMed ID: 19637942
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.
    Dransfield MT; Bourbeau J; Jones PW; Hanania NA; Mahler DA; Vestbo J; Wachtel A; Martinez FJ; Barnhart F; Sanford L; Lettis S; Crim C; Calverley PM
    Lancet Respir Med; 2013 May; 1(3):210-23. PubMed ID: 24429127
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased systemic inflammation is a risk factor for COPD exacerbations.
    Groenewegen KH; Postma DS; Hop WC; Wielders PL; Schlösser NJ; Wouters EF;
    Chest; 2008 Feb; 133(2):350-7. PubMed ID: 18198263
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Socioeconomic status and prognosis of COPD in Denmark.
    Lange P; Marott JL; Vestbo J; Ingebrigtsen TS; Nordestgaard BG
    COPD; 2014 Aug; 11(4):431-7. PubMed ID: 24568315
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blood eosinophil count and risk of pneumonia hospitalisations in individuals with COPD.
    Vedel-Krogh S; Nordestgaard BG; Lange P; Vestbo J; Nielsen SF
    Eur Respir J; 2018 May; 51(5):. PubMed ID: 29650563
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictors of treatment with antibiotics and systemic corticosteroids for acute exacerbations of asthma and chronic obstructive pulmonary disease in primary care.
    Salwan AA; Spigt M; Laue J; Melbye H
    BMC Fam Pract; 2015 Mar; 16():40. PubMed ID: 25887285
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bronchoscopic validation of the significance of sputum purulence in severe exacerbations of chronic obstructive pulmonary disease.
    Soler N; Agustí C; Angrill J; Puig De la Bellacasa J; Torres A
    Thorax; 2007 Jan; 62(1):29-35. PubMed ID: 16928715
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stepwise withdrawal of inhaled corticosteroids in COPD patients receiving dual bronchodilation: WISDOM study design and rationale.
    Magnussen H; Watz H; Kirsten A; Decramer M; Dahl R; Calverley PM; Towse L; Finnigan H; Tetzlaff K; Disse B
    Respir Med; 2014 Apr; 108(4):593-9. PubMed ID: 24477080
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of corticosteroids in chronic obstructive pulmonary disease.
    Calverley PM
    Semin Respir Crit Care Med; 2005 Apr; 26(2):235-45. PubMed ID: 16088440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exacerbation history, severity of dyspnoea and maintenance treatment predicts risk of future exacerbations in patients with COPD in the general population.
    Marott JL; Çolak Y; Ingebrigtsen TS; Vestbo J; Nordestgaard BG; Lange P
    Respir Med; 2022 Feb; 192():106725. PubMed ID: 34972025
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.